Author: Ken Dropiewski

HeartFlow Announces Enrollment of First Three Patients in FUSION Trial

National Health Care Institute of the Netherlands-supported study to evaluate role of the HeartFlow Analysis in reducing unnecessary invasive procedures REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that physicians at Erasmus MC Hospital (Rotterdam NL) have enrolled the first three patients in the […]

IDTechEx Dissects the Market for Solid-state Batteries in New Report

BOSTON, Sept. 2, 2021 /PRNewswire/ — IDTechEx has recently launched the new version of their market research report on solid-state batteries – “Solid-State and Polymer Batteries 2021-2031: Technology, Forecasts, Players“.  This report identifies key players within the market; discusses manufacturing challenges and how companies are addressing limitations; explores lithium metal as […]

Sequana Medical announces H1 2021 results and provides business update

alfapump® – Positive results from second interim analysis of POSEIDON pivotal study; awaiting FDA approval on POSEIDON pivotal study expansion alfapump® – FDA regulatory submission now expected in mid-2023 due to worldwide supply shortage of electronic components; European commercial activities and clinical studies unaffected alfapump DSR® – Strong top-line results from RED DESERT; interim results […]

Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology

The Series A was led by a major strategic investor along with a significant investment from ShangBay Capital as well as other investors. Laplace Interventional plans to use the funds raised from this round towards achieving its preclinical milestones. MINNEAPOLIS–(BUSINESS WIRE)–Minnesota based Laplace Interventional, a medical device company developing a […]

MedAlliance Announces First Patient Enrolled in the 3,300 Patient Landmark Sirolimus DEB vs DES Study

GENEVA, Sept. 1, 2021 /PRNewswire/ — MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study “SELUTION DeNovo”. This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], versus a limus drug-eluting stent [DES]. This is the largest DEB study ever initiated, with […]

Cardax Refocuses on ZanthoSyn® Consumer Health Business

Company focusing on consumer revenue growth with reduced cost structure Pharmaceutical assets may be monetized through licensing or sale Other strategic alternatives under consideration Board of Directors restructured in connection with new strategy HONOLULU, Aug. 31, 2021 /PRNewswire/ — Cardax, Inc., announced today that it is refocusing its business strategy on its […]

KardiaMobile 6L is Superior to One Lead Personal Devices

MOUNTAIN VIEW, Calif., Sept. 1, 2021 /PRNewswire/ — AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced the KardiaMobile® 6L device was found to be superior to single lead devices according to results from the largest study to assess the reliability of the detection of atrial fibrillation (AF) through […]

Healogics® Raises Awareness of Peripheral Artery Disease (PAD) to Help Reduce Amputations

JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ — Healogics, the nation’s leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September. Through this campaign, Healogics is supporting the American Heart Association’s goal to reduce amputations by 20% by 2030 through increased PAD Awareness, diagnosis and treatment. […]

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)

Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a […]